2022年12月最新中科院JCR期刊分区表数据（升级版）已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | LEUKEMIA LEUKEMIA LetPub评分 9.1
50人评分
我要评分
声誉 10.0 影响力 8.3 速度 9.7 | |||||||||||||||||||||||||
| 期刊ISSN | 0887-6924 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
| E-ISSN | 1476-5551 | |||||||||||||||||||||||||
| 2021-2022最新影响因子 （数据来源于搜索引擎） | 12.883 点击查看影响因子趋势图 | |||||||||||||||||||||||||
| 2021-2022自引率 | 3.40%点击查看自引率趋势图 | |||||||||||||||||||||||||
| h-index | 176 | |||||||||||||||||||||||||
| CiteScore |
| |||||||||||||||||||||||||
| 期刊简介 | Leukemia publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction, molecular targets for therapy and more. We publish a range of content types including original research articles, reviews, letters, correspondence and comments that elaborate on significant advances in the field and cover topical issues. | |||||||||||||||||||||||||
| 期刊官方网站 | https://www.nature.com/leu | |||||||||||||||||||||||||
| 期刊投稿网址 | https://mts-leu.nature.com/ | |||||||||||||||||||||||||
| 作者指南网址 | https://www.nature.com/leu/authors-and-referees | |||||||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足LEUKEMIA的语言要求，还能让LEUKEMIA编辑和审稿人得到更好的审稿体验，让稿件最大限度地被LEUKEMIA编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||
| 是否OA开放访问 | No 备注：Archive content is freely available after five years. | |||||||||||||||||||||||||
| 通讯方式 | NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON, ENGLAND, N1 9XW | |||||||||||||||||||||||||
| 出版商 | Springer Nature | |||||||||||||||||||||||||
| 涉及的研究方向 | 医学-血液学 | |||||||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||
| 出版周期 | Monthly | |||||||||||||||||||||||||
| 出版年份 | 1997 | |||||||||||||||||||||||||
| 年文章数 | 231点击查看年文章数趋势图 | |||||||||||||||||||||||||
| Gold OA文章占比 | 39.73% | |||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 85.71% | |||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2021-2022年最新版） | WOS分区等级：1区
| |||||||||||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0887-6924%5BISSN%5D | |||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 一般,3-6周 | |||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 很难 | |||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在LEUKEMIA顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Author: Guo Y1,2, Zhou Y3, Yamatomo S1,2, Yang H1,2, Zhang P1,2, Chen S1,2, Nimer SD1,2, Zhao ZJ4, Xu M1,2, Bai J5,6, Yang FC7,8. Journal: Leukemia. 2019 May;33(5):1287-1291. doi: 10.1038/s41375-018-0347-y. Epub 2019 Jan 16. PubMed DOI |
| 2. | Mutant p53 enhances leukemia-initiating cell self-renewal to promote leukemia development. Author: Nabinger SC1, Chen S2, Gao R1, Yao C1,3, Kobayashi M1, Vemula S1, Fahey AC1, Wang C1, Daniels C1, Boswell HS4, Sandusky GE5, Mayo LD1, Kapur R1, Liu Y6,7. Journal: Leukemia. 2019 Jan 23. doi: 10.1038/s41375-019-0377-0. [Epub ahead of print] PubMed DOI |
| 3. | CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Author: Schmidt L1,2, Heyes E1, Scheiblecker L1, Eder T1, Volpe G3,4, Frampton J3, Nerlov C5, Valent P6, Grembecka J7, Grebien F8,9. Journal: Leukemia. 2019 Jan 24. doi: 10.1038/s41375-019-0382-3. [Epub ahead of print] PubMed DOI |
| 4. | Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Author: Chen R1, Zhu M2,3, Chaudhari RR1, Robles O3, Chen Y1, Skillern W1, Qin Q1,4, Wierda WG5, Zhang S1, Hull KG2,3, Romo D6,7, Plunkett W8,9. Journal: Leukemia. 2019 Jan 30. doi: 10.1038/s41375-018-0364-x. [Epub ahead of print] PubMed DOI |
| 5. | What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Author: Zhao H1, Huang XF1, Gao XM1, Cai H1, Zhang L1, Feng J1, Cao XX1, Zhou DB1, Li J2. Journal: Leukemia. 2019 Apr;33(4):1023-1029. doi: 10.1038/s41375-019-0391-2. Epub 2019 Jan 30. PubMed DOI |
| 6. | Destabilization of AETFC through C/EBPα-mediated repression of LYL1 contributes to t(8;21) leukemic cell differentiation. Author: Zhang MM1, Liu N2, Zhang YL1, Rong B3, Wang XL1, Xu CH2, Xie YY1, Shen S4, Zhu J1, Nimer SD5, Chen Z1, Chen SJ1, Roeder RG6, Lan F3, Wang L7, Huang QH8, Sun XJ9. Journal: Leukemia. 2019 Feb 12. doi: 10.1038/s41375-019-0398-8. [Epub ahead of print] PubMed DOI |
| 7. | Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Author: Canaani J1, Labopin M2, Itälä-Remes M3, Blaise D4, Socié G5, Forcade E6, Maertens J7, Wu D8, Malladi R9, Cornelissen JJ10, Huynh A11, Bourhis JH12, Esteve J13, Mohty M2, Nagler A14,15. Journal: Leukemia. 2019 Mar 7. doi: 10.1038/s41375-019-0439-3. [Epub ahead of print] PubMed DOI |
| 8. | Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. Author: He X1, Xiao X2, Li Q2, Jiang Y2, Cao Y3, Sun R3, Jin X1, Yuan T2, Meng J2, Ma L2, Lu W2, Lyu C2, Liu K4, Zhao M5,6. Journal: Leukemia. 2019 Mar 7. doi: 10.1038/s41375-019-0437-5. [Epub ahead of print] PubMed DOI |
| 9. | Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Author: Sun Y1, Ding N2, Song Y2, Yang Z1, Liu W3, Zhu J4, Rao Y5. Journal: Leukemia. 2019 Mar 11. doi: 10.1038/s41375-019-0440-x. [Epub ahead of print] PubMed DOI |
| 10. | Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Author: Harrington CT1,2, Sotillo E1,3, Robert A4, Hayer KE5, Bogusz AM6, Psathas J1,7, Yu D1,8, Taylor D5,9, Dang CV10, Klein P2,11, Hogarty MD2,9,12, Geoerger B13,14, El-Deiry WS15, Wiels J4, Thomas-Tikhonenko A16,17,18,19. Journal: Leukemia. 2019 Mar 26. doi: 10.1038/s41375-019-0454-4. [Epub ahead of print] PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共1条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
